Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31305215 | 1.00 | MAPT (0.71) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL28003049 | 0.85 | GAA (0.67) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL216813 | 0.84 | MAPT (0.55) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL30780911 | 0.84 | MAPT (0.55) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL1926207 | 0.83 | MAPT (1.00) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL10021493 | 0.82 | MAPT (0.53) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL16372649 | 0.82 | MAPT (0.74) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL3008120 | 0.82 | MAPT (0.74) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL15783811 | 0.81 | MAPT (0.56) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL14320533 | 0.80 | MAPT (0.71) | MAPTGAATSHRMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024238872-A2 | ISOINDOLINONE-GLUTARIMIDE ANTIBODY CONJUGATES, AND USES THEREOF | FIREFLY BIO, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-3941424-A1 | HAIR COLORANT COMPOSITIONS | Wella International Operations Switzerland Sàrl (CH) | 2022-01-26 | — | — | EP | disclosed |
| WO-2021031788-A1 | PHENYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, USE THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 中国药科大学 | 2021-02-25 | — | — | WO | disclosed |
| WO-2020188001-A1 | HAIR COLORANT COMPOSITIONS | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2020-09-24 | — | — | WO | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| EP-3345904-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.a. (IT) | 2018-07-11 | — | — | EP | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9643961-B2 | Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2017-05-09 | — | — | US | disclosed |
| EP-1877031-A2 | HAIR COLOURING KITS AND METHODS OF USE THEREOF | The Procter and Gamble Company (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007122597-A2 | AMIDE SURFACTANT THICKENING SYSTEMS FOR HAIR COLOURING AND BLEACHING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007102119-A1 | THICKENED HAIR COLOURANT AND BLEACHING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007097928-A2 | HAIR COLOURING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2006118879-A1 | MICELLE THICKENING SYSTEMS FOR HAIR COLOURANT AND BLEACHING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006118942-A2 | HAIR COLOURING KITS AND METHODS OF USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006060570-A2 | HAIR COLOURING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060569-A2 | POLYMER THICKENED HAIR COLOURING AND BLEACHING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060565-A2 | HIGH LEVEL CARBONATE AND/OR OXIDANT HAIR COLOURING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060568-A1 | THICKENED HAIR COLOURANT AND BLEACHING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 470/4885GAA 742/4885TSHR 1137/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAPT 438/4885GAA 698/4885TSHR 1024/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAPT 438/4885GAA 698/4885TSHR 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.